See more : PT Pelita Samudera Shipping Tbk (PSSI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of BioLargo, Inc. (BLGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLargo, Inc., a leading company in the Chemicals industry within the Basic Materials sector.
You may be interested
- Immunovant, Inc. (IMVT) Income Statement Analysis – Financial Results
- Arbutus Biopharma Corporation (ABUS) Income Statement Analysis – Financial Results
- MVV Energie AG (MVV1.DE) Income Statement Analysis – Financial Results
- Answear.com S.A. (ANR.WA) Income Statement Analysis – Financial Results
- Patentus S.A. (PAT.WA) Income Statement Analysis – Financial Results
BioLargo, Inc. (BLGO)
About BioLargo, Inc.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | 1.36M | 516.21K | 281.11K | 127.58K | 111.55K | 167.95K | 65.54K | 156.19K | 156.76K | 138.13K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 749.84K | 833.54K | 1.88M | 2.39M | 1.93M | 2.50M | 1.30M | 4.50M | 7.70M | 9.40M | 9.80M | 6.70M |
| Cost of Revenue | 6.08M | 3.03M | 1.43M | 1.20M | 945.00K | 743.00K | 322.72K | 105.88K | 62.07K | 56.00K | 29.66K | 39.78K | 44.76K | 125.48K | 114.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.29K | 0.00 | 119.41K | 119.18K | 22.41K | 0.00 | 0.00 | 0.00 | 0.00 | 5.10M | 6.40M | 7.80M | 7.70M | 5.20M |
| Gross Profit | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | 621.00K | 193.50K | 175.23K | 65.52K | 55.55K | 138.29K | 25.76K | 111.43K | 31.28K | 23.58K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | -20.29K | 0.00 | 630.43K | 714.35K | 1.86M | 2.39M | 1.93M | 2.50M | 1.30M | -600.00K | 1.30M | 1.60M | 2.10M | 1.50M |
| Gross Profit Ratio | 50.32% | 48.56% | 43.58% | 50.49% | 49.22% | 45.53% | 37.48% | 62.34% | 51.35% | 49.80% | 82.34% | 39.30% | 71.34% | 19.95% | 17.07% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.08% | 85.70% | 98.81% | 100.00% | 100.00% | 100.00% | 100.00% | -13.33% | 16.88% | 17.02% | 21.43% | 22.39% |
| Research & Development | 2.28M | 1.32M | 1.37M | 1.34M | 1.47M | 1.72M | 1.63M | 1.38M | 684.55K | 642.92K | 742.25K | 126.02K | 99.50K | 100.56K | 170.12K | 113.75K | 131.35K | 129.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 6.14M | 5.26M | 4.43M | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 246.00K | 246.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.06M | 6.73M | 6.17M | 7.47M | 6.14M | 5.26M | 4.43M | 3.71M | 3.55M | 2.79M | 2.00M | 4.61M | 3.17M | 4.12M | 3.96M | 4.83M | 2.99M | 1.63M | 944.81K | 971.94K | 2.34M | 2.16M | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -74.00K | -55.00K | -137.00K | -218.00K | 73.00K | 71.13K | 13.74K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | 0.00 | 0.00 | 0.00 | 8.55K | -661.87K | 3.45M | 268.46K | -1.32M | 258.13K | 186.53K | 189.35K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.34M | 7.98M | 7.48M | 8.67M | 7.39M | 6.88M | 6.09M | 5.11M | 4.25M | 3.45M | 2.76M | 4.74M | 3.27M | 4.23M | 5.25M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.35M | 1.50M | 7.42M | 2.86M | 453.95K | 1.99M | 1.87M | 1.57M | 1.20M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Cost & Expenses | 16.42M | 11.00M | 8.91M | 9.88M | 8.34M | 7.62M | 6.41M | 5.22M | 4.31M | 3.50M | 2.79M | 4.78M | 3.32M | 4.36M | 5.36M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.37M | 1.50M | 7.54M | 2.98M | 476.36K | 1.99M | 1.87M | 1.57M | 1.20M | 6.50M | 8.00M | 9.40M | 8.80M | 5.70M |
| Interest Income | 0.00 | 53.00K | 234.00K | 1.92M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.53K | 35.96K | 0.00 | 153.51K | 0.00 | 255.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 91.00K | 53.00K | 234.00K | 1.92M | 4.00M | 3.49M | 3.86M | 3.13M | 994.67K | 348.15K | 281.59K | 616.35K | 793.26K | 1.67M | 1.63M | 1.15M | 1.56M | 344.88K | 242.49K | 250.70K | 344.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 45.00K | 20.00K | 58.00K | 65.00K | 50.00K | 29.84K | 15.89K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | -796.55K | 246.10K | -4.60K | 660.30K | 9.94K | 176.10K | 268.46K | 197.19K | 258.13K | 186.53K | 189.35K | -100.00K | -300.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | -7.23M | -5.73M | -4.93M | -4.07M | -3.38M | -2.61M | -4.71M | -3.15M | -4.19M | -4.11M | -5.00M | -3.05M | -2.56M | -698.70K | -967.34K | -1.71M | -1.54M | -2.77M | -4.46M | 1.60M | 664.46K | 245.16K | 1.12M | -100.00K | -2.30M | -400.00K | -200.00K | 1.00M | 1.00M |
| EBITDA Ratio | -34.23% | -85.16% | -248.83% | -299.22% | -341.21% | -449.49% | -1,136.19% | -1,749.86% | -3,346.62% | -3,030.56% | -1,553.32% | -7,189.59% | -2,018.88% | -2,751.20% | 3,370.18% | 0.00% | -3,918.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.77% | -225.65% | 246.39% | 27.78% | 12.68% | 44.96% | -7.69% | -51.11% | -5.19% | -2.13% | 10.20% | 14.93% |
| Operating Income | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | -6.41M | -5.90M | -4.93M | -4.18M | -3.39M | -2.62M | -4.72M | -3.16M | -4.20M | -14.01M | -6.05M | -3.78M | -1.76M | -944.81K | -971.94K | -2.37M | -1.50M | -6.79M | -2.15M | -112.29K | 406.32K | 58.63K | 935.07K | 100.00K | -2.00M | -300.00K | -200.00K | 1.00M | 1.00M |
| Operating Income Ratio | -34.23% | -87.00% | -252.11% | -306.17% | -348.09% | -470.09% | -1,141.98% | -1,755.52% | -3,277.49% | -3,040.35% | -1,559.82% | -7,197.88% | -2,023.91% | -2,678.33% | -10,138.78% | 0.00% | -4,730.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -905.25% | -257.85% | -5.98% | 16.99% | 3.03% | 37.39% | 7.69% | -44.44% | -3.90% | -2.13% | 10.20% | 14.93% |
| Total Other Income/Expenses | -449.00K | 61.00K | -458.00K | -2.12M | -4.74M | -4.28M | -3.65M | -3.14M | -895.55K | -348.15K | -281.59K | -616.35K | -793.26K | -1.54M | -8.76M | 59.99K | -1.48M | 796.55K | -246.10K | -246.10K | -344.83K | 6.74K | 121.94K | 35.96K | -1.41M | 153.51K | 222.88K | 255.93K | 200.00K | 200.00K | 100.00K | 300.00K | 0.00 | -1.00M |
| Income Before Tax | -4.64M | -5.13M | -6.89M | -9.70M | -11.44M | -10.70M | -9.55M | -8.07M | -5.08M | -3.74M | -2.90M | -5.33M | 0.00 | -4.07M | -22.77M | -5.99M | -5.26M | -965.82K | -1.19M | -1.22M | -2.71M | -1.49M | -6.65M | -2.11M | -1.52M | 559.83K | 281.51K | 1.19M | 300.00K | -1.80M | -200.00K | 300.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | -37.90% | -87.22% | -272.38% | -398.85% | -614.72% | -784.16% | -1,849.34% | -2,872.35% | -3,979.42% | -3,352.46% | -1,727.49% | -8,138.27% | 0.00% | -2,599.36% | -16,482.26% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.54% | -80.78% | 23.40% | 14.56% | 47.62% | 23.08% | -40.00% | -2.60% | 3.19% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | -636.00K | 483.00K | 766.00K | 3.31M | -790.00K | 3.43M | 2.89M | 874.50K | -47.45K | -372.92K | 0.00 | 793.26K | 1.54M | 10.39M | 1.09M | 1.48M | 344.88K | -3.61K | 250.70K | 4.91M | 3.44M | 0.00 | 3.47K | -11.54K | 196.71K | 103.68K | 554.64K | -100.00K | -100.00K | -100.00K | 100.00K | -1.00M | -900.00K |
| Net Income | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M | -10.22M | -9.12M | -7.84M | -5.06M | -3.69M | -2.53M | -5.33M | -3.95M | -5.74M | -15.61M | -7.14M | -5.26M | -1.31M | -1.19M | -1.22M | -7.62M | -4.94M | -6.65M | -2.12M | -1.51M | 531.12K | 261.83K | 968.36K | -300.00K | -1.70M | -100.00K | 200.00K | 1.00M | 900.00K |
| Net Income Ratio | -28.65% | -76.41% | -291.47% | -430.35% | -792.53% | -749.34% | -1,766.19% | -2,788.89% | -3,962.92% | -3,309.92% | -1,505.44% | -8,138.27% | -2,531.80% | -3,663.12% | -11,302.54% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.96% | -80.16% | 22.20% | 13.54% | 38.72% | -23.08% | -37.78% | -1.30% | 2.13% | 10.20% | 13.43% |
| EPS | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| Weighted Avg Shares Out | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
| Weighted Avg Shares Out (Dil) | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
BioLargo acquires proprietary sodium-sulfur battery technology
BioLargo Inc (OTCQB:BLGO) has announced its acquisition of a proprietary sodium-sulfur battery technology that it has identified as a high-value solution that has a series of features that sets it apart from currently available battery technologies in the market. The company said it has...
BioLargo sees 1Q revenue continuing to break records thanks to its Pooph branded pet-odor remover
BioLargo Inc (OTCQB:BLGO) revealed that its first-quarter 2023 revenue has already surpassed its previous record quarterly revenue set last quarter. The Westminster, California-based company said the revenue growth is driven primarily by sales of the Pooph branded pet-odor control product sold by...
BioLargo says its Aqueous Electrostatic Concentrator combats a toxic soup of PFAS to meet likely new drinking water standards
BioLargo Inc (OTCQB:BLGO) revealed that its Aqueous Electrostatic Concentrator (AEC) technology is capable of treating water to below the US Environmental Protection Agency's (EPA's) newly proposed drinking water standards for a toxic soup of PFAS, or per- and polyfluoroalkyl substances....
BioLargo subsidiary appoints medical industry veterans, Nicholas Valeriani and Linda Park to its board
BioLargo Inc (OTCQB:BLGO) said its subsidiary Clyra Medical Technologies Inc has appointed two medical industry veterans, Nicholas Valeriani and Linda Park, as new members of its board of directors Valeriani has decades of executive experience in the medical device industry,...
BioLargo's 2022 revenue doubles up 2021 in new preliminary results
BioLargo Inc (OTCQB:BLGO) has announced preliminary 2022 financial results, revealing full-year revenue that more than doubled the company's 2021 figure. The full-service environmental engineering company posted top-line revenue of more than $5.75 million, over 125% higher than its 2021 revenue.
BioLargo drops pet odor control product Pooph into Walmart stores across the US
BioLargo Inc (OTCQB:BLGO) has announced that its pet odor control product line Pooph is now available in over 600 Walmart stores across the US. Pooph is based on BioLargo's proprietary odor control technology and is being marketed by Ikigai Marketing Works...
BioLargo, Inc. (BLGO) Q3 2022 Earnings Call Transcript
BioLargo, Inc. (OTCQB:BLGO) Q3 2022 Earnings Conference Call November 16, 2022 5:00 PM ET Company Participants Brian Loper - Investor Relations, ClearThink Capital Dennis Calvert - Chief Executive Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen. And welcome...
BioLargo boasts 3Q revenue growth of 111% to record $1.5 million
BioLargo Inc (OTCQB:BLGO) said it achieved revenue of a record US$1.5 million for third quarter 2022 and $3.7 million for the nine months ended September 30, 2022, increases of 111% and 117% respectively over the same periods in 2021. The full-service...
BioLargo Q3 2022 Earnings Results Webcast and Conference Call on Wednesday, November 16, 2022 - 5 PM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / November 10, 2022 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 16, 2022, at 2:00 pm...
BioLargo subsidiary presents pilot program results at Canadian conference, showing up to 100% removal of contaminants from wastewater
BioLargo Inc said positive results from a municipal wastewater treatment pilot were presented at the Canadian Water and Wastewater Association's annual conference by its subsidiary, BioLargo Water, showing how its water treatment technology is a powerful yet energy- and cost-efficient solution...
Source: https://incomestatements.info
Category: Stock Reports